2851885-95-3
Chemical Structure
ARV-393
- No. CAS: 2851885-95-3
- Formula:C46H53ClFN9O7
- Molecular Weight:898.42
InChIKey: ZOGOEUHUEFKKTD-VVDHFOCHSA-N
SMILES: ClC1=CN=C(N2CCC(O[C@@H]3C[C@@H](N4CCC(C5=C(F)C(CN(C6CCC(NC6=O)=O)C7=O)=C7C=C5)CC4)C3)CC2)N=C1NC8=CC(C=C(OCC(NC)=O)C(N9C(C)C)=O)=C9C=C8
Biological Activity: ARV-393 is a BCL6 PROTAC degrader. ARV-393 forms a complex with BCL6 and Cereblon, induces BCL6 ubiquitination, and mediates BCL6 degradation via the ubiquitin-proteasome system. ARV-393 enhances CD20 expression, interferon pathway activity and antigen presentation. ARV-393 induces tumor growth inhibition and regression. ARV-393 can be used in research related to non-Hodgkin's lymphoma, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma and follicular lymphoma[1][2][3][4].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ARV-393 | 99.75% | ARV-393 is a BCL6 PROTAC degrader. ARV-393 forms a complex with BCL6 and Cereblon, induces BCL6 ubiquitination, and mediates BCL6 degradation via the ubiquitin-proteasome system. ARV-393 enhances CD20 expression, interferon pathway activity and antigen presentation. ARV-393 induces tumor growth inhibition and regression. ARV-393 can be used in research related to non-Hodgkin's lymphoma, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma and follicular lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sherman D. Abstract ND05: The discovery of ARV-393, a potent, orally bioavailable BCL6 targeting PROTAC® for the treatment of Non-Hodgkin’s Lymphoma[J]. Cancer Research, 2024, 84(7_Supplement): ND05-ND05.
- [2]. Caimi P F, et al. Phase 1 study of ARV-393, a PROTAC BCL6 degrader, in advanced non-hodgkin lymphoma[J]. Blood, 2024, 144: 6505.
- [3]. Van Acker A, et al. ARV-393, a PROTAC BCL6 degrader, combined with the CD20× CD3 bispecific glofitamab in a preclinical model of high-grade B-cell lymphoma (HGBCL)[J]. Blood, 2025, 146: 1520.
- [4]. Caimi P, et al. Abstract PO-010: Trial in Progress: Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma[J]. Blood Cancer Discovery, 2024, 5(3_Supplement): PO-010-PO-010.
